NCT03014804View on ClinicalTrials.gov

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2022

Conditions
Giant Cell GlioblastomaGliosarcomaOligodendrogliomaRecurrent GlioblastomaSmall Cell Glioblastoma
Interventions
BIOLOGICAL

autologous dendritic cells pulsed with tumor lysate antigen Vaccine

Given ID

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Northwest Biotherapeutics

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Brain Tumor Funders Collaborative

UNKNOWN

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03014804 - Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter